LivaNova (NASDAQ:LIVN) Downgraded by Wall Street Zen to Buy

LivaNova (NASDAQ:LIVN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Other analysts also recently issued research reports about the stock. Robert W. Baird lifted their price target on shares of LivaNova from $63.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research note on Monday. Barclays boosted their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Mizuho upped their target price on shares of LivaNova from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.43.

LivaNova Stock Down 0.8%

Shares of NASDAQ:LIVN opened at $63.36 on Friday. The business’s 50 day simple moving average is $55.14 and its two-hundred day simple moving average is $50.84. The firm has a market cap of $3.46 billion, a P/E ratio of -15.84 and a beta of 1.02. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. LivaNova has a 52-week low of $32.48 and a 52-week high of $64.45.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in the company. Amundi increased its position in shares of LivaNova by 7.2% during the first quarter. Amundi now owns 196,435 shares of the company’s stock valued at $7,362,000 after acquiring an additional 13,142 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in LivaNova by 20.3% in the second quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock worth $4,599,000 after purchasing an additional 17,252 shares during the last quarter. Aberdeen Group plc grew its stake in LivaNova by 18.1% in the 2nd quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock valued at $14,712,000 after purchasing an additional 50,076 shares during the period. EP Wealth Advisors LLC purchased a new stake in shares of LivaNova during the 1st quarter valued at $293,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of LivaNova during the 2nd quarter worth $1,713,000. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.